Application of carbon nanoparticles combined with refined extracapsular anatomy in endoscopic thyroidectomy.

Objective: To evaluate the value of refined extracapsular anatomy combined with carbon nanoparticle suspension tracing technology for protecting parathyroid function and the thoroughness of lymph node dissection in the central region during endoscopic thyroid cancer surgery. Patients and methods: Retrospective clinical data analysis was performed on 108 patients who underwent endoscopic thyroid cancer surgery at the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital) from November 2019 to November 2022. Before surgery, thyroid function tests, color Doppler ultrasounds and neck-enhanced CT scans were performed on all patients. Cytopathological diagnosis obtained via ultrasound-guided fine-needle aspiration served as confirmation for the primary diagnosis. It was determined whether to perform a total thyroidectomy or a hemithyroidectomy (HT) together with preventive unilateral (ipsilateral) central neck dissection. Follow-up times were 1 to 34 months. Results: Transient neuromuscular symptoms were present in 3.70% (4/108) cases, with no permanent neuromuscular symptoms or permanent hypoparathyroidism. Regarding transient hypoparathyroidism, the patients recovered after three months and did not need long-term calcium supplementation. The number of harvested LNs (mean± SD) was 5.54 ± 3.84, with ≤5 in 57.41% (62/108) and >5 in 42.59% (46/108) cases. The number of patients with metastatic LNs was 37.96% (41/108), with ≤2 in 65.85% (27/41) and >2 in 34.15% (14/41) cases. Conclusions: Fine extracapsular anatomy combined with carbon nanoparticle suspension tracing is effective in endoscopic thyroid cancer surgery. It can improve the thoroughness of prophylactic central neck dissection and recognition of the parathyroid gland and avoid parathyroid injury and other complications to effectively protect parathyroid function.

MiR-758-3p regulates papillary thyroid cancer cell proliferation and migration by targeting TAB1.

Previous studied revealed that miR-758-3p was abnormally expressed in cancer patients. However, its role and underlying mechanism in papillary thyroid cancer (PTC) remains unclear. Expression of miR-758-3p in PTC cell lines was analyzed using quantitative real-time PCR. It was observed that miR-758-3p expression was significantly downregulated in PTC cell lines. Overexpression of miR-758-3p inhibited PTC cell proliferation, invasion but promoted cell apoptosis in vitro. Further study demonstrated that TGF-ß activated kinase 1 binding protein 1 (TAB1) was a direct target of miR-758-3p and TAB1 expression was suppressed by miR-758-3p overexpression. Moreover, TAB1 was shown to be a mediator for the roles of miR-758-3p in PTC. Therefore, our study established a tumor-suppressive role for miR-758-3p in the inhibition of PTC progression, which may be employed as a novel prognostic marker and as an effective therapeutic target for PTC.